• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Issues Related to Recombinant Human Growth Hormone Utilization and Optimization in a Health Plan Setting

Supplements and Featured PublicationsGrowth Hormone Treatment: Balancing Cost, Safety, and Outcome in a Managed Care Environment [CME/CPE
Volume 17
Issue 18 Suppl

Healthcare expenditures in the United States are high and continue to increase; as a result, providers and managed care organizations have to evaluate the impact of specialty drugs such as recombinant human growth hormone (rhGH) therapy. As the number of approved indications for rhGH therapy has increased, so too have questions about the appropriate allocation of resources for such therapy. This is particularly true for the recent rhGH indications in children with idiopathic short stature and those short for gestational age who fail to attain normal growth percentiles. With a large increase in the number of children eligible for rhGH therapy, questions arise as to whether all eligible children should be treated with rhGH, and what are the appropriate length of treatment and optimal treatment outcomes. These are important questions for managed care organizations who must determine the treatment parameters that produce the best outcomes in children. The primary disease burdens of growth hormone deficiency (GHD) in adults are the changes in body composition and metabolic parameters, and reduced quality of life, all of which are associated with improvements following rhGH therapy. In adults, the primary economic burden of GHD is healthcare-related costs such as increased hospital days and clinic visits.

(Am J Manag Care. 2011;17:eS11-eS15)Burden of Growth Hormone Deficiency in Adults: Body Composition

The effects of growth hormone deficiency (GHD) in adults have been studied with greater intensity over the last 2 decades. An early study demonstrated that male and female patients with hypopituitarism and GHD had a 3-fold greater risk of fractures than control patients despite receiving regular hormonal replacement therapy (excluding growth hormone).1 Further studies have confirmed that GHD decreases bone mass and that the decrease in bone mass correlates with the severity of GHD.2 GHD also causes reduced lean body mass, increased body fat, fatigue, and a reduced ability to perform daily activities.1-6 Recently published Endocrine Society guidelines on treating adult GHD recognize the improvements in body composition associated with recombinant human growth hormone (rhGH) therapy in adults.7 A 10-year study of rhGH therapy showed that bone mineral density increased progressively with treatment, with greater benefits observed in men. Women without adequate estrogen levels did not benefit to the same extent as men.8

Burden of GHD in Adults: Cardiovascular Disease Surrogate Outcomes

Data for 2589 patients with GHD from the Pfizer International Metabolic Database (also known as KIMS) showed that patients with GHD had elevated total and low-density lipoprotein (LDL) cholesterol, increased waist circumference and body mass index (BMI), and increased blood pressure.9 The percentage of those with elevated total cholesterol increased with age, and approximately 71% of all patients with GHD had cholesterol levels above 200 mg/dL. Trends for increased LDL-cholesterol and triglyceride levels showed similar increases above normal. After adjusting for BMI, age, and sex, studies have reported a 20% increase in carotid intima-medial thickness in adults with GHD compared with normal adults.6 Leonsson and colleagues examined the inflammatory markers C-reactive protein (CRP) and interleukin-6 (IL-6) and found that patients with GHD showed a 2-fold increase in IL-6 compared with matched controls. CRP was also elevated compared with non-obese patients, but was similar to controls when corrected for BMI.4 The cumulative elevation of CVD risk factors suggested an increased risk for CVD; however, controlled trials specifically analyzing cardiovascular end points are required to further elucidate the risk associated with GHD in adults. Many studies have shown that CVD risk factors improved with rhGH therapy, including improved total cholesterol levels, a trend toward improved LDL cholesterol levels, and a reduction in blood pressure.9-11 Reports on surrogate CVD end points with rhGH therapy are encouraging; however, long-term controlled trials are required to confirm these results.

Quality of Life and Economic Burden: Improvement With rhGH Therapy

Quality of Life (QOL) is significantly reduced in adults with GHD compared with the general population.12-14 Although there is variability among studies assessing the effects of GHD on QOL, a recent review of studies suggests that the type of tools used to measure QOL may affect outcomes. Generic tools, such as the Nottingham Health Profile or the Psychological General Well Being Scale, tend to show less robust results compared with disease-specific tools such as the Questions on Life Satisfaction-Hypopituitarism and the Adult Growth Hormone Deficiency Assessment questionnaire.15 Not only do the disease-specific tools show an increased effect of the disease on QOL at baseline, they generally show a greater improvement in QOL after treatment with rhGH.

Koltowska-Häggström and colleagues used a database that included patients with GHD from England, Wales, the Netherlands, Spain, and Sweden to study QOL using the disease-specific questionnaire Quality of Life—Assessment of Growth Hormone Deficiency in Adults (QOL-AGHDA).12 Those with GHD had much lower QOL-AGHDA scores compared with the general population from each country. Patients with GHD had the lowest scores in QOL dimensions related to memory, concentration, and tiredness, followed by tenseness, self-confidence, and socializing. Long-term rhGH treatment (at least 5 years) tended to normalize the difference in scores between those with and without GHD.16

The economic burden of GHD has been reported primarily in studies that show an improvement in healthcare-related costs after treatment with rhGH. Patients with GHD report increased sick leave from work and increased healthcare access, including increased hospital days and provider visits, and the need for assistance with daily activities (Table).17 Using healthcare-related data from KIMS, Hernberg-Ståhl and colleagues showed a high rate of sick leave from work and other healthcare-related costs in patients with GHD. After treatment with rhGH for 12 months, sick leave, hospital days, doctor visits, leisure time, physical activity, satisfaction with physical activity, the need for assistance with daily activities, and QOL (AGHDA scores) significantly improved.

Pediatric Burden of GHD and Other Growth-Related Disorders

The burden of GHD in children is more difficult to evaluate, since there is some debate about disability associated with short stature. However, short stature can have a negative impact on the ability to perform daily activities if an adult height of at least 150 centimeters is not attained. Furthermore, those with other conditions that affect height, such as Prader-Willi syndrome, can be adversely impacted by associated factors, such as increased body fat.18 As discussed by Rogol in this supplement,19 the psychosocial burden of short stature is controversial, although many studies show that children of short stature are negatively impacted, especially with respect to behavioral issues.20,21

In a Japanese study by Lee and colleagues of 116 children with idiopathic short stature (ISS) and 127 with GHD, the Child Behavior Checklist (CBCL) was used to assess the psychosocial profiles of children aged 4 to 15 years.22 Children normal children. Subscales that measure QOL also indicated a significant increase in social and attention problems in those with ISS or GHD compared with controls. A placebo-controlled study of 68 children (53 males, 15 females) measured psychosocial differences in treated or untreated children with marked ISS (those with a height at least 2.5 standard deviations below the normal population mean). Patients received rhGH 0.074 mg/kg or placebo (subcutaneously 3 times per week) until their height velocity decreased to less than 1.5 centimeters per year.20 CBCL and Self-Perception Profile scores were within normal range at baseline and no significant differences were observed between groups during the first 2 years. Thereafter, those given rhGH showed an improvement in CBCL scores for behavior problems compared with those given placebo (Figure 1).20

Cost-Effectiveness of rhGH Therapy in Children

The cost of treating children with rhGH is estimated at $52,634 per inch (or 2.54 cm).22 Because this is a high-cost treatment, benefits for the patient are an important aspect of justifying the expense for managed care organizations. Only a few long-term studies have evaluated the costs and benefits of rhGH therapy in children with ISS. One study used the Wessex Development and Evaluation Committee report to evaluate quality-adjusted life-years (QALYs). The QALY scale included a disability rating, a physical discomfort scale covering 5 levels of pain, and a distress scale covering 5 levels of emotional distress. The cost-effectiveness and cost utility of treating children aged 5 to 16 years with rhGH was estimated at approximately $8900 per normal height year gained and $37,000 per QALY gained, respectively (Figure 2).23

To maintain the cost-effectiveness of rhGH therapy in ISS, it is important to identify the condition early and start treatment as soon as possible.22 The study by Lee and colleagues showed that earlier age at initiation of rhGH therapy was associated with reduced cost per inch. This is partially because rhGH is dosed by weight; younger children weigh less than older children and therefore require a lower dose of rhGH. Identifying children who will be most responsive to therapy is also critical for maintaining cost-effectiveness of treatment, especially because there is great variability in responsiveness to rhGH treatment among children with ISS. If all eligible children with ISS were treated in the United States, the cost would be substantial.22 With such high costs of treatment, to achieve optimal results, it is important to identify children who will benefit most from treatment and determine the appropriate age for rhGh therapy.

In the article by Rogol in this supplement,19 the criteria for diagnosing GHD and other conditions causing short stature were discussed. However, not all managed care organizations cover ISS, even though it is an FDA-approved indication for rhGH therapy.24-26 In addition to meeting the criteria for diagnosis of GHD, some managed care organizations may also require that a patient be followed for up to 6 months by a pediatric endocrinologist prior to the initiation of rhGH therapy. If all criteria for diagnosis are maintained, then the patient with ISS and GHD had higher CBCL scores compared with can be initiated on rhGH therapy with a follow-up evaluation after 6 months.27 Some managed care organizations require an annual reassessment of growth.25 The dose may be increased during the second 6-month treatment period, but rhGH therapy may be discontinued if the patient does not achieve a growth velocity of at least 4 centimeters per year, or for continued treatment over 1 year, a growth rate at least 50% higher than the previous year. Some managed care organizations may discontinue rhGH therapy if the height increase is less than 3 centimeters per year or if there is evidence of fusion of epiphyses during treatment.26

Case Studies

Presented here are 3 case studies that illustrate the individualized management of rhGH therapy.

Case 1

Jenny is a 6-year-old female. Her parents were referred to an endocrinologist because Jenny’s growth rate did not seem normal. It was determined that her height was 3 SDs below the normal population mean. The endocrinology clinical exam and provocation test indicated that she had GHD. Jenny was started on rhGH therapy at a dose of 0.24 mg/kg/week. At the end of 2 years, she attained a height 0.5 SD below the normal population mean. Treatment was continued for 1 more year and then discontinued. Her final adult height was 0.5 SD less than the normal population mean.

Case 2

John is a 7-year-old male with a height 2.25 SDs less than the normal population mean. All provocation tests did not show any evidence of GHD. He was diagnosed with ISS and was initiated on rhGH therapy, which was titrated to a final dose of 0.35 mg/kg/week. At the end of a 6-month trial period, his height was 2.0 SDs less than the normal population mean and 1.8 SDs less than mean after 1 year. Because John was responding to treatment, rhGH therapy was continued for 4 years. John attained an adult height of 1.0 SD less than the normal population mean.

Case 3

Robert is an 8-year-old male with a height 2.8 SDs less than the normal population mean. He was diagnosed with ISS and initiated on rhGH therapy. The rhGH dose was titrated to a final dose of 0.40 mg/kg/week. At the end of the 6-month trial, his height remained 2.8 SDs less than the normal population mean. After conferring with the patient and family, it was determined that adherence was not the reason for lack of response, so treatment was discontinued.


GHD is a healthcare and QOL burden for adults and is associated with increased risk for surrogates for CVD, such as high blood pressure. Therapy with rhGH has been shown to reduce the burden of GHD and improve QOL in adults. Studies evaluating the cost benefit of treating GHD and other conditions that cause short stature in children suggest that rhGH therapy improves the burden of GHD and QALYs. In children with ISS, those receiving rhGH therapy demonstrated fewer behavioral problems than children not receiving rhGH therapy.Author affiliations: Department of Pharmacotherapy and Pharmacotherapy Outcomes Research, University of Utah, Salt Lake City, UT (NAN); SelectHealth, Inc, Salt Lake City, UT (JDD).

Funding source: This activity is supported by an educational grant from Novo Nordisk, Inc.

Author disclosures: Dr Nickman reports grants/research support from Novartis Pharmaceuticals. Dr Dunn reports consultancy/advisory board membership with Novo Nordisk, Inc.

Authorship information: Concept and design (JDD, NAN); acquisition of data (NAN); analysis and interpretation of data (JDD, NAN); drafting of the manuscript (JDD, NAN); critical revision of the manuscript for important intellectual content (JDD, NAN); statistical analysis (NAN); and supervision (NAN).

Address correspondence to: Nancy A. Nickman, PhD, University of Utah, 30 S 2000 E, Room 258, Salt Lake City, UT 84112. E-mail: nancy .nickman@pharm.utah.edu.

  1. Rosén T, Wilhelmsen L, Landin-Wilhelmsen K, Lappas G, Bengtsson BA. Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. Eur J Endocrinol. 1997;137:240-245.
  2. Colao A, Di Somma C, Pivonello R, et al. Bone loss is correlated to the severity of growth hormone deficiency in adult patients with hypopituitarism. J Clin Endocrinol Metab. 1999;84:1919-1924.
  3. Blum WF, Shavrikova EP, Edwards DJ, et al. Decreased quality of life in adult patients with growth hormone deficiency compared with general populations using the new, validated, self-weighted questionnaire, questions on life satisfaction hypopituitarism module. J Clin Endocrinol Metab. 2003;88:4158-4167.
  4. Leonsson M, Hulthe J, Johannsson G, et al. Increased Interleukin-6 levels in pituitary-deficient patients are independently related to their carotid intima-media thickness. Clin Endocrinol (Oxf). 2003;59:242-250.
  5. Sartorio A, Agosti F, De Col A, et al. Muscle strength and power, maximum oxygen consumption, and body composition in middle-aged short-stature adults with childhood-onset growth hormone deficiency. Arch Med Res. 2008;39:78-83.
  6. Sen F, Demirturk M, Abaci N, et al. Endothelial nitric oxide synthase intron 4a/b polymorphism and early atherosclerotic changes in hypopituitary GH-deficient adult patients. Eur J Endocrinol. 2008;158:615-622.
  7. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96:1587-1609.
  8. Götherstrom G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J. Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. Eur J Endocrinol. 2007;156:55-64.
  9. Abs R, Feldt-Rasmussen U, Mattsson AF, et al. Determinants of cardiovascular risk in 2589 hypopituitary GH-deficient adults - a KIMS database analysis. Eur J Endocrinol. 2006;155:79-90.
  10. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a meta-analysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2004;89:2192-2199.
  11. Oliviera JL, Aguiar-Oliveira M, D’Oliveira A, et al. Congenital growth hormone (GH) deficiency and atherosclerosis: effects of GH replacement in GH-naïve adults. J Clin Endocrinol Metab. 2007;92:4664-4670.
  12. Koltowska-Häggström M, Mattsson AF, Monson JP, et al. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? Eur J Endocrinol. 2006;155:101-109.
  13. Moock J, Albrecht C, Friedrich N, et al. Health-related quality of life and IGF-1 in GH-deficient adult patients on GH replacement therapy: analysis of the German KIMS data and the Study of Health in Pomerania. Eur J Endocrinol. 2009;160:17-24.
  14. Rosilio M, Blum WF, Edwards DJ, et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab. 2004;89:1684-1693.
  15. Webb SM. Measurements of quality of life in patients with growth hormone deficiency. J Endocrinol Invest. 2008;31(9)(suppl):52-55.
  16. Koltowska-Häggström M, Mattsson AF, Shalet SM. Assessment of quality of life in adult patients with GH deficiency: KIMS contribution to clinical practice and pharmacoeconomic evaluations. Eur J Endocrinol. 2009;161(suppl 1):S51-S64.
  17. Hernberg-Ståhl E, Luger A, Abs R, et al. Healthcare consumption decreases in parallel with improvements in quality of life during GH replacement in hypopituitary adults with GH deficiency. J Clin Endocrinol Metab. 2001;86:5277-5281.
  18. Carrel AL, Myers SE, Whitman BY, Eickhoff J, Allen DB. Long-term growth hormone therapy changes the natural history of body composition and motor function in children with Prader-Willi syndrome. J Clin Endocrinol Metab. 2010;95:1131-1136.
  19. Rogol AD. Clinical and humanistic aspects of growth hormone deficiency and growth-related disorders. Am J Manag Care. 2011;17(18):eS4-eS10.
  20. Ross JL, Sandberg DE, Rose SR, et al. Psychological adaptation in children with idiopathic short stature treated with growth hormone or placebo. J Clin Endocrinol Metab. 2004;89:4873-4878.
  21. Tanaka T, Tai S, Morisaki Y, et al. Evaluation of quality of life in children with GH deficiency and idiopathic short stature using the Child Behavior Checklist. Clin Pediatr Endocrinol. 2009;18:15-22.
  22. Lee JM, Davis MM, Clark SJ, Hofer TP, Kemper AR. Estimated cost-effectiveness of growth hormone therapy for idiopathic short stature. Arch Pediatr Adolesc Med. 2006;160:263-269.
  23. Joshi AV, Munro V, Russell MW. Cost-utility of somatropin (rDNA origin) in the treatment of growth hormone deficiency in children. Curr Med Res Opin. 2006;22:351-357.
  24. Clinical policy bulletin: growth hormone (GH) and growth hormone antagonists. Aetna Inc Web site. http://www.aetna.com/cpb/medical/data/100_199/0170.html. Updated 2011. Accessed November 2, 2011.
  25. Cigna pharmacy coverage policy: somatropin. Cigna Web site. http://www.cigna.com/assets/docs/health-care-professionals/coverage_positions/ph_4012_recombinant_human_growth_hormones.pdf. Updated January 1, 2011. Accessed November 2, 2011.
  26. Pharmacy medical necessity guidelines: growth hormone replacement therapy tufts health plan. Tufts Associated Health Plans, Inc. Web site. http://www.tuftshealthplan.com/providers/pdf/pharmacy_criteria/Recombinate_HGH_Therapy.pdf. Updated September 13, 2011. Accessed December 1, 2011.
  27. Growth hormone prior authorization coverage criteria. Blue Cross Blue Shield of Alabama Web site. https://www.bcbsal.org/providers/pharmMedicarePolicies/final/4020.pdf. Updated February 2, 2011. Accessed November 2, 2011.
© 2024 MJH Life Sciences
All rights reserved.